PHARMA RESULTS. NATURAL DELIVERY. EXCLUSIVELY DISTRIBUTED BY ORYGN
THE SCIENCE IS REAL
Peer-reviewed clinical research. Independent trials, and global recognition — every product backed by uncompromising evidence.
$50M+
INVESTED IN RESEARCH
10+
YEARS OF STUDIES
8+
PUBLISHED STUDIES
13
FDA CLAIMS
80+
COUNTRIES
98%
BIOAVAILABILITY
PEER-REVIEWED RESEARCH
CLINICAL TRIALS & PUBLISHED STUDIES
Over $50 million invested and more than a decade of independent research. A curated index of peer-reviewed studies and clinical trials supporting the core bioactives in every ORYGN product.
Clinical Trial
Iron Deficiency Anemia: Ferritin & Hemoglobin Levels Following ProGo® Supplementation vs. Whey Protein
Journal of Nutrition & Food Sciences · 2015
n = 48 · Placebo-controlled vs. whey protein isolate · 6 weeks · 16g/day+140% ferritin (restored to normal); +14% hemoglobin vs. +2% in whey group (p<0.05). Basis for 6 FDA structure/function claims & Health Canada qualified claims.
View Full Study
Clinical Trial
Weight Management & Metabolic Biomarkers: Randomised Placebo-Controlled Study on BMI in Overweight Adults
Journal of Nutrition & Food Sciences
Overweight subjects · Placebo-controlled vs. WPI · 42 days · 16g/day−5.9% BMI (p<0.05); significant changes in 4 metabolism-relevant serum biomarkers; consistent 3–6% reduction in fasting blood glucose.
View Full Study
CLINICAL TRIAL
Investigating the Efficacy of 18-Week Salmon Protein Hydrolysate Supplementation on Metabolic Inflammation, Well-Being & Cosmetic Outcomes
Functional Foods in Health and Disease · 2024 · Vol.14(11): 814–842
n = 20 · Open-label, single-arm · 128 days · 4g/day · KGK Science Inc.+10.24% perceived energy (women +14.55%); −9% oxidative stress; HMOX1 ↑4.09×; FTH1 ↑3.77×; skin/hair/nail +24% (women +34.5%); IL-5, IL-8 & CRP reduced.
View Full Study
Published Study
A Randomized, Double-Blinded Cross-Over Study Comparing Increase in Blood Leucine Levels after Ingestion of Hydrolyzed Salmon and Whey Proteins in Healthy Young Men
Nutrition & Food Technology Open Access · 2017
n = 6 · Randomised double-blind crossover · 16g doses · Norwegian School of Sport SciencesProGo® reached peak blood leucine 15 min faster than WPC-80; rapid aminoacidemia; comparable insulin response.
View Full Study
In Vitro
Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides
Marine Drugs · MDPI · 2024 · 22(11): 490
In vitro · Currie C. et al. · Hofseth BioCare
Smallest ProGo® peptide fraction activates GLP-1 & GIP receptors; pancreatic islet cell protection; DPP-IV inhibition; improved glucose uptake into muscle.
View Full Study
In Vitro / Animal
Soluble Protein Hydrolysate Ameliorates Gastrointestinal Inflammation and Injury in TNBS-Induced Colitis in Mice
Biomolecules · 2022 · 12(9): 1287
Mouse model of colitis · Wei J. et al. · Stanford University & Hofseth BioCare
ProGo® significantly reduced colon tissue injury, inflammatory cell infiltrates & oxidative stress. HMOX1 upregulation confirmed. Led by Dr. Karl Sylvester MD, Stanford.
View Full Study
In Vitro
Glucoregulatory Bioactivity of ProGo® Peptides: DPP-IV Inhibition and Glucose Uptake in Muscle Cells
Marine Drugs · MDPI · 2024
In vitro · Hofseth BioCare
ProGo® peptides demonstrated potent DPP-IV inhibition and improved glucose uptake into muscle — augmenting insulin action, boosting satiety, reducing metabolic disease risk factors.
View Full Study
In Vitro
Antioxidant Gene Expression: ProGo® Upregulates 16 Oxidative Protective Genes Including FTH1, HMOX1 & ALOX12
Hofseth BioCare / Stanford University · Pre-clinical
Human cell lines · HBC & Stanford University
ProGo® upregulated 16 oxidative protective genes and downregulated 9 oxidative stress genes. FTH1, HMOX1 & ALOX12 showed notable fold-change supporting observed clinical benefits.
View Full Study
In The Press
NEWS & GLOBAL COVERAGE
Real coverage from trade press, financial media, and industry publications — tracking the science, the deals, and the momentum behind ProGo® and Fission Holdings.
Yahoo Finance · Euronext
Hofseth BioCare & Fission Holdings Sign Exclusive ProGo® License & Supply Agreement for Over $5M
May 22, 2026
HBC entered into an Exclusive License and Supply Agreement granting Fission Holdings worldwide rights to market and sell ProGo® in the affiliate, network marketing, and MLM channel. Fission shall purchase a minimum of $3M of ProGo® by January 31, 2027, with an annualised projection of over $5M.
Read Full Announcement
NutraIngredients
"Salmon-derived peptides may activate GLP-1: Hofseth BioCare data"
November 2024
Read Article
NutraIngredients
"ProGo® may offer anti-inflammatory and cosmetic benefits — 34.5% hair, skin & nail improvement in women"
November 2024
Read Article
Nutraceuticals World
"HBC & RFI Ingredients Present ProGo® Bioactive Peptide Metabolic Mechanisms at SupplySide West"
October 2024
Read Article
Undercurrent News
"Hofseth Biocare signs two-year exclusivity deal on peptides with US distributor Fission Holdings"
May 2026
Read Article
Yahoo Finance
"ProGo® — World's First Consumer Health GLP-1 & GIP Receptor Agonist with Muscle Mass Protection via Myostatin & Activin A Inhibition"
September 2025
HBC whitepaper confirming ProGo's triple-action profile: GLP-1/GIP activation, myostatin inhibition, and anti-inflammatory bioactivity.
Read Article
Hofseth BioCare
"Study Unveils the Potential of ProGo® Bioactive Peptides to Regulate Glucose & Improve Metabolic Health"
April 2024
Published in Marine Drugs (MDPI). DPP-IV inhibition and improved glucose uptake confirmed. Consistent with 3–6% fasting blood glucose reductions in human trials.
Read Article
Regulatory Recognition
FDA & Health Canada Approved Claims
ProGo® has earned the highest levels of regulatory recognition available in North America — an NDI designation from the FDA, thirteen FDA Structure/Function Claims, and four Qualified Health Claims from Health Canada. These are not marketing statements. They are government-recognized, science-backed, and legally defensible.
NDI Designation
FDA New Dietary Ingredient
United States · 2022
ProGo® has received FDA New Dietary Ingredient (NDI) status — the highest safety rating available in the US market. NDI classification confirms ProGo® is both safe for human consumption and legally marketable as a dietary supplement ingredient in the United States.
View FDA Announcement
Non-GMO Verified
Non-GMO Project Verified
United States · Non-GMO Project
ProGo® raw material has been granted approval by the Non-GMO Project — enabling co-branding on premium consumer product packaging and unlocking distribution through organic and natural retail channels including Nestlé-owned Garden of Life.
Asia Passported
Health Canada Claims Recognized in Asia
Canada · Asia-Pacific
Health Canada's Qualified Health Claims (QHCs) are internationally recognized by most Asian countries and have been passported for use in those markets — enabling ORYGN to leverage regulatory credibility across Japan, South Korea, China, and the broader Asia-Pacific region.
United States Food & Drug Administration
13 FDA Structure/Function Claims
The FDA did not oppose any of HBC's claim notices within the statutory review period — confirming ProGo® is legally permitted to carry the following claims on US-market labels and marketing materials.
Iron & Blood Health
"Supports healthy ferritin and hemoglobin levels."
Iron & Blood Health
"Helps maintain iron-rich blood."
Energy
"Promotes energy utilization."
Blood Cell Production
"Supports red blood cell production."
GI & Immune Health
"Supports gastrointestinal and immune system health."
Iron Absorption
"Assists in iron absorption from your daily diet."
Skin Health
"Helps with dry skin."
Skin Health
"Reduces wrinkles and promotes skin smoothness."
Skin Barrier
"Prevents an increase in trans-epidermal water loss."
Skin Health
"Supports skin health and appearance."
Fatigue
"Reduces occasional fatigue and general feelings of occasional tiredness."
Antioxidant
"Reduces oxidative stress caused by free radicals."
Antioxidant
"Acts as an antioxidant."
YAHOO FINANCE
Hofseth BioCare & Fission Holdings Sign Exclusive Agreement
EURONEXT · MAY 2026
HBC entered into an Exclusive License and Supply Agreement granting Fission Holdings worldwide rights...
Global Footprint
Recognized On Every Continent
Over $50M invested. A decade of peer-reviewed studies. Distribution across 80+ countries on every continent.
Partnerships & Endorsements
Trusted By The Best In The Field
ORYGN licenses ProGo® under Fission Holdings, LLC, which holds the worldwide exclusive rights to import, market, distribute, and sell ProGo® within the Affiliate, Network Marketing, and MLM channel — working alongside the world's leading research institutions, clinical partners, and distribution organisations.
Exclusive Channel Distribution · Affiliate & Network Marketing
ProGo® Exclusively Distributed by Fission Holdings LLC
ORYGN has licensed ProGo® distribution from Fission Holdings LLC, which holds the worldwide exclusive rights to import, market, distribute, and sell HBC's ProGo® ingredient within the Affiliate, Network Marketing, and Multi-Level Marketing (MLM) channel — the only company in the world authorized to do so. This exclusivity is secured by multi-million dollar purchase guarantees, confirmed by Hofseth BioCare ASA's official Oslo Børs stock exchange announcement on May 22, 2026.
View Official HBC Announcement
Exclusive Channel Distributor · Worldwide MLM/Affiliate Rights
Fission Holdings LLC
Tulsa, Oklahoma · USA
Holds exclusive worldwide rights to distribute ProGo® in the affiliate and network marketing channel. Parent operating entity of ORYGN, with direct reach to consumers across 80+ countries.
Bioactive Ingredient Supplier
Hofseth BioCare ASA
Ålesund, Norway
Source and manufacturer of ProGo® — a patented, clinically-validated salmon-derived bioactive peptide from sustainable Norwegian Atlantic salmon offcuts. Listed on Oslo Børs (HBC).
Clinical Research Partner
Stanford University
Palo Alto, California
Led by Dr. Karl Sylvester MD, Stanford published the landmark gut health/colitis study (Biomolecules, 2022) confirming ProGo's immunomodulatory action and HMOX1 upregulation.
Clinical Research Partner
KGK Science Inc.
London, Ontario · Canada
Conducted the 128-day vitality, inflammation, and cosmetic outcomes trial (Functional Foods in Health and Disease, 2024). One of North America's leading CROs for nutraceutical trials.
Clinical Research Partner
Jim LaValle & Metabolic Elite
United States
Strategic partnership to develop premium performance products using ProGo®, OmeGo®, and CalGo® — debuted at A4M Longevity Fest, Las Vegas.
